|
G |
Dek |
DEK proto-oncogene |
multiple interactions |
ISO |
DEK protein results in decreased chemical synthesis of and results in increased uptake of Pyrrolidonecarboxylic Acid |
CTD |
PMID:28558019 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Pyrrolidonecarboxylic Acid analog |
CTD |
PMID:26820058 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions decreases activity |
EXP ISO |
Captopril inhibits the reaction [Pregabalin results in increased expression of ACE protein] Captopril inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; Captopril inhibits the reaction [AGT protein results in increased expression of ACE protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of ACE mRNA]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of ACE protein] Captopril results in decreased activity of ACE protein |
CTD |
PMID:26851370 PMID:31629013 PMID:33007385 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
decreases response to substance multiple interactions |
ISO EXP |
ACE2 gene SNP results in decreased susceptibility to Captopril Captopril inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; Captopril inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 protein] Captopril inhibits the reaction [Pregabalin results in decreased expression of ACE2 protein] |
CTD |
PMID:17473847 PMID:31629013 PMID:33007385 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of ACTA2 protein] Captopril inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein] |
CTD |
PMID:31181250 PMID:33007385 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP ISO |
[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of AGT protein]; Captopril inhibits the reaction [bisphenol A results in increased expression of AGT protein]; Captopril inhibits the reaction [Pregabalin results in decreased expression of AGT protein] Captopril inhibits the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]; Captopril inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; Captopril inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; Captopril inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; Captopril inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; Captopril inhibits the reaction [AGT protein results in increased expression of ACE protein]; Captopril inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of AGT protein]; Captopril inhibits the reaction [AGT protein results in increased expression of AGTR1 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; Captopril inhibits the reaction [AGT protein results in increased expression of VIM protein]; Captopril inhibits the reaction [LEPR protein affects the expression of AGT protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of AGT protein alternative form]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of AGT protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; Captopril inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Captopril inhibits the reaction [Cadmium Chloride results in increased expression of AGT protein] |
CTD |
PMID:28130181 PMID:31181250 PMID:31629013 PMID:33007385 PMID:35844137 PMID:38027817 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
EXP ISO |
Captopril inhibits the reaction [Pregabalin results in increased expression of AGTR1 protein] Captopril inhibits the reaction [AGT protein results in increased expression of AGTR1 protein]; Captopril inhibits the reaction [LEPR protein affects the expression of AGTR1A mRNA]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of AGTR1 protein] |
CTD |
PMID:28130181 PMID:31629013 PMID:33007385 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Captopril inhibits the reaction [Glucose results in increased expression of AKT1 mRNA] |
CTD |
PMID:38115276 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
EXP |
Captopril inhibits the reaction [Methotrexate results in increased expression of and results in increased secretion of ALPL protein] |
CTD |
PMID:27269004 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
ISO |
Captopril inhibits the reaction [LEPR protein affects the expression of BDKRB2 protein] |
CTD |
PMID:28130181 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Calb1 |
calbindin 1 |
multiple interactions |
ISO |
Captopril promotes the reaction [LEPR protein affects the expression of CALB1 protein] |
CTD |
PMID:28130181 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
Captopril promotes the reaction [LEPR protein affects the expression of CAR2 mRNA] |
CTD |
PMID:28130181 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
Captopril inhibits the reaction [Methotrexate results in increased expression of CASP3 protein] Captopril inhibits the reaction [Glucose results in increased expression of CASP3 mRNA] |
CTD |
PMID:27269004 PMID:38115276 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
Captopril inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
Captopril inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Gli1 |
GLI family zinc finger 1 |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein] |
CTD |
PMID:31181250 |
|
NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
|
|
G |
Gli2 |
GLI family zinc finger 2 |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein] |
CTD |
PMID:31181250 |
|
NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574
|
|
G |
Gli3 |
GLI family zinc finger 3 |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein] |
CTD |
PMID:31181250 |
|
NCBI chr17:49,438,567...49,709,712
Ensembl chr17:49,438,567...49,709,712
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
Captopril inhibits the reaction [Methotrexate results in increased expression of and results in increased secretion of GOT1 protein] |
CTD |
PMID:27269004 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Captopril inhibits the reaction [Methotrexate results in increased expression of and results in increased secretion of GPT protein] |
CTD |
PMID:27269004 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of IL6 protein]; Captopril inhibits the reaction [bisphenol A results in increased expression of IL6 protein] Captopril inhibits the reaction [Glucose results in increased expression of IL6 mRNA] |
CTD |
PMID:38027817 PMID:38115276 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
EXP |
[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of KNG1 protein]; Captopril inhibits the reaction [bisphenol A results in increased expression of KNG1 protein] |
CTD |
PMID:38027817 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Lepr |
leptin receptor |
multiple interactions affects response to substance |
ISO |
Captopril inhibits the reaction [LEPR protein affects the expression of AGT protein]; Captopril inhibits the reaction [LEPR protein affects the expression of AGTR1A mRNA]; Captopril inhibits the reaction [LEPR protein affects the expression of BDKRB2 protein]; Captopril inhibits the reaction [LEPR protein affects the expression of PTH protein]; Captopril inhibits the reaction [LEPR protein affects the expression of VEGFA mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of CALB1 protein]; Captopril promotes the reaction [LEPR protein affects the expression of CAR2 mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of MMP9 mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of RUNX2 mRNA]; Captopril promotes the reaction [LEPR protein affects the expression of VDR protein] LEPR protein affects the susceptibility to Captopril |
CTD |
PMID:28130181 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
multiple interactions |
EXP ISO |
Captopril inhibits the reaction [Pregabalin results in decreased expression of MAS1 protein] Captopril inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of MAS1 protein] |
CTD |
PMID:31629013 PMID:33007385 |
|
NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709
|
|
G |
Mir146a |
microRNA 146a |
multiple interactions |
EXP |
captopril inhibits the reaction [ischemia-reperfusion injury increases expression of Mir146a miRNA in kidney] |
RGD |
PMID:27760486 |
RGD:155882556 |
NCBI chr10:27,848,516...27,848,610
Ensembl chr10:27,848,516...27,848,610
|
|
G |
Mir320a |
microRNA 320a |
multiple interactions |
EXP |
captopril inhibits the reaction [ischemia-reperfusion injury increases expression of Mir320a miRNA in kidney] |
RGD |
PMID:27760486 |
RGD:155882556 |
NCBI chr15:45,516,392...45,516,473
Ensembl chr15:45,516,392...45,516,473
|
|
G |
Mlkl |
mixed lineage kinase domain like pseudokinase |
multiple interactions |
ISO |
Captopril inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MLKL protein] |
CTD |
PMID:35844137 |
|
NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Captopril promotes the reaction [LEPR protein affects the expression of MMP9 mRNA] |
CTD |
PMID:28130181 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Captopril inhibits the reaction [Methotrexate results in increased expression of NOS2 protein] |
CTD |
PMID:27269004 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
Captopril inhibits the reaction [Pregabalin results in increased expression of NPPB protein] |
CTD |
PMID:31629013 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP |
Captopril inhibits the reaction [Pregabalin results in decreased expression of PRKACA protein] |
CTD |
PMID:31629013 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Ptch1 |
patched 1 |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]; Captopril inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein] |
CTD |
PMID:31181250 |
|
NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
Captopril inhibits the reaction [Methotrexate results in increased expression of PTGS2 protein] Captopril inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA] |
CTD |
PMID:27269004 PMID:38115276 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pth |
parathyroid hormone |
multiple interactions |
ISO |
Captopril inhibits the reaction [LEPR protein affects the expression of PTH protein] |
CTD |
PMID:28130181 |
|
NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Captopril inhibits the reaction [Glucose results in increased phosphorylation of and results in increased localization of RELA protein] |
CTD |
PMID:38115276 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
multiple interactions |
ISO |
Captopril inhibits the reaction [Cadmium Chloride results in increased expression of RIPK3 protein] |
CTD |
PMID:35844137 |
|
NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
Captopril promotes the reaction [LEPR protein affects the expression of RUNX2 mRNA] |
CTD |
PMID:28130181 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Shh |
sonic hedgehog signaling molecule |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein] |
CTD |
PMID:31181250 |
|
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
|
|
G |
Smo |
smoothened, frizzled class receptor |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein] |
CTD |
PMID:31181250 |
|
NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Captopril inhibits the reaction [Methotrexate results in decreased expression of and results in decreased activity of SOD1 protein] |
CTD |
PMID:27269004 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]; Captopril inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein] |
CTD |
PMID:38027817 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of TNF protein]; Captopril inhibits the reaction [bisphenol A results in increased expression of TNF protein] Captopril inhibits the reaction [Glucose results in increased expression of TNF mRNA] |
CTD |
PMID:38027817 PMID:38115276 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
Captopril inhibits the reaction [Glucose results in increased expression of VCAM1 mRNA] |
CTD |
PMID:38115276 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions |
ISO |
Captopril promotes the reaction [LEPR protein affects the expression of VDR protein] |
CTD |
PMID:28130181 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Captopril inhibits the reaction [LEPR protein affects the expression of VEGFA mRNA] |
CTD |
PMID:28130181 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
Captopril inhibits the reaction [AGT protein results in increased expression of VIM protein]; Captopril inhibits the reaction [Silicon Dioxide results in increased expression of VIM protein] |
CTD |
PMID:33007385 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO |
Clindamycin results in increased expression of and results in increased activity of CYP3A4 protein Clindamycin results in increased expression of CYP3A4 mRNA |
CTD |
PMID:18505790 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Clindamycin results in increased expression of MMP13 mRNA |
CTD |
PMID:20338993 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
RT1-A2 |
RT1 class Ia, locus A2 |
affects expression |
ISO |
Clindamycin affects the expression of HLA-E mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,870,939...4,910,183
|
|
G |
RT1-Db1 |
RT1 class II, locus Db1 |
affects expression |
ISO |
Clindamycin affects the expression of HLA-DRB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258
|
|
|
G |
Pon1 |
paraoxonase 1 |
decreases activity |
ISO |
clindamycin phosphate results in decreased activity of PON1 protein |
CTD |
PMID:16880604 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression increases localization multiple interactions |
ISO |
domoic acid results in increased expression of BAX mRNA domoic acid results in increased localization of BAX protein Carbachol inhibits the reaction [domoic acid results in increased localization of BAX protein] |
CTD |
PMID:18293405 PMID:19200344 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects expression |
ISO |
domoic acid affects the expression of BCL2 mRNA |
CTD |
PMID:18293405 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Carbachol inhibits the reaction [domoic acid results in increased activity of CASP3 protein] |
CTD |
PMID:19200344 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
domoic acid results in increased expression of GCLC mRNA; domoic acid results in increased expression of GCLC protein |
CTD |
PMID:23315585 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression decreases response to substance affects response to substance |
ISO |
domoic acid results in increased expression of GCLM mRNA; domoic acid results in increased expression of GCLM protein [GCLM protein results in decreased susceptibility to domoic acid] which results in decreased susceptibility to 2,3-dimethoxy-1,4-naphthoquinone; [GCLM protein results in decreased susceptibility to domoic acid] which results in decreased susceptibility to Hydrogen Peroxide; GCLM protein results in decreased susceptibility to domoic acid; GCLM results in decreased susceptibility to domoic acid GCLM affects the susceptibility to domoic acid |
CTD |
PMID:17804861 PMID:19200344 PMID:23315585 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
increases phosphorylation |
EXP |
domoic acid results in increased phosphorylation of GRIA1 protein |
CTD |
PMID:19564213 |
|
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Pvalb |
parvalbumin |
increases expression |
ISO |
domoic acid results in increased expression of PVALB protein |
CTD |
PMID:26797589 |
|
NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561
|
|
G |
Wdr35 |
WD repeat domain 35 |
increases expression multiple interactions |
EXP |
domoic acid results in increased expression of WDR35 mRNA; domoic acid results in increased expression of WDR35 protein 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline inhibits the reaction [domoic acid results in increased expression of WDR35 protein]; Edaravone inhibits the reaction [domoic acid results in increased expression of WDR35 protein] |
CTD |
PMID:23289926 |
|
NCBI chr 6:31,771,315...31,831,450
Ensembl chr 6:31,771,360...31,831,029
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases response to substance |
ISO |
ABCC1 protein results in decreased susceptibility to Fosinopril |
CTD |
PMID:22095822 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases response to substance increases export multiple interactions |
ISO |
ABCC2 protein results in decreased susceptibility to Fosinopril ABCC2 protein results in increased export of Fosinopril desloratadine inhibits the reaction [ABCC2 protein results in increased export of Fosinopril]; Loratadine inhibits the reaction [ABCC2 protein results in increased export of Fosinopril]; Methotrexate inhibits the reaction [ABCC2 protein results in increased export of Fosinopril] ABCC2 protein affects the reaction [Fosinopril affects the export of Methotrexate] |
CTD |
PMID:22095822 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Adipor2 |
adiponectin receptor 2 |
increases expression |
EXP |
fosinopril increases expression of adipor2 mRNA in rat liver |
RGD |
PMID:19076162 |
RGD:2307264 |
NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
|
|
G |
Afp |
alpha-fetoprotein |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of AFP protein] |
CTD |
PMID:29859236 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agt |
angiotensinogen |
decreases expression |
EXP |
Fosinopril results in decreased expression of AGT protein |
CTD |
PMID:12411096 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
multiple interactions |
EXP |
Fosinopril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of BMPR2 mRNA] |
CTD |
PMID:17803470 |
|
NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of CCND1 mRNA] |
CTD |
PMID:29859236 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased activity of GPT protein] |
CTD |
PMID:29859236 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Kl |
Klotho |
increases expression |
EXP |
Fosinopril results in increased expression of KL mRNA; Fosinopril results in increased expression of KL protein |
CTD |
PMID:21051829 |
|
NCBI chr12:490,402...531,417
Ensembl chr12:490,399...530,080
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of MMP2 protein] |
CTD |
PMID:29859236 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
EXP |
Fosinopril results in decreased expression of MMP9 mRNA; Fosinopril results in decreased expression of MMP9 protein [Valsartan co-treated with Fosinopril] results in decreased expression of MMP9 mRNA; [Valsartan co-treated with Fosinopril] results in decreased expression of MMP9 protein |
CTD |
PMID:21051829 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in decreased expression of NFKB1 protein] |
CTD |
PMID:29859236 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos3 |
nitric oxide synthase 3 |
affects expression |
EXP |
Fosinopril affects the expression of NOS3 mRNA; Fosinopril affects the expression of NOS3 protein |
CTD |
PMID:18209565 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Pde1a |
phosphodiesterase 1A |
affects expression |
EXP |
Fosinopril affects the expression of PDE1A mRNA; Fosinopril affects the expression of PDE1A protein |
CTD |
PMID:18209565 |
|
NCBI chr 3:64,745,140...65,025,178
Ensembl chr 3:64,747,269...65,024,874
|
|
G |
Pde1c |
phosphodiesterase 1C |
affects expression |
EXP |
Fosinopril affects the expression of PDE1C mRNA; Fosinopril affects the expression of PDE1C protein |
CTD |
PMID:18209565 |
|
NCBI chr 4:85,300,858...85,777,948
Ensembl chr 4:85,300,858...85,863,219
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of RELA protein] |
CTD |
PMID:29859236 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Serpine1 |
serpin family E member 1 |
decreases expression multiple interactions |
EXP |
Fosinopril results in decreased expression of SERPINE1 mRNA; Fosinopril results in decreased expression of SERPINE1 protein [Valsartan co-treated with Fosinopril] results in decreased expression of SERPINE1 mRNA; [Valsartan co-treated with Fosinopril] results in decreased expression of SERPINE1 protein |
CTD |
PMID:21051829 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc15a1 |
solute carrier family 15 member 1 |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine] |
CTD |
PMID:18713951 |
|
NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
|
|
G |
Slc15a2 |
solute carrier family 15 member 2 |
multiple interactions |
EXP |
Fosinopril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine] |
CTD |
PMID:18713951 |
|
NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of TGFB1 protein] |
CTD |
PMID:29859236 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression multiple interactions |
EXP |
Fosinopril results in decreased expression of TIMP1 mRNA; Fosinopril results in decreased expression of TIMP1 protein [Valsartan co-treated with Fosinopril] results in decreased expression of TIMP1 mRNA; [Valsartan co-treated with Fosinopril] results in decreased expression of TIMP1 protein |
CTD |
PMID:21051829 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of TNF protein] |
CTD |
PMID:29859236 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Fosinopril inhibits the reaction [Diethylnitrosamine results in increased expression of VEGFA protein] |
CTD |
PMID:29859236 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
EXP |
Kainic Acid results in increased expression of ABCB1A mRNA; Kainic Acid results in increased expression of ABCB1A protein |
CTD |
PMID:14706787 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
increases expression |
EXP |
Kainic Acid results in increased expression of ABCB1B mRNA; Kainic Acid results in increased expression of ABCB1B protein |
CTD |
PMID:14706787 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
ISO |
Kainic Acid results in increased expression of ABCG2 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Aco2 |
aconitase 2 |
multiple interactions decreases activity |
EXP |
6-Cyano-7-nitroquinoxaline-2,3-dione inhibits the reaction [Kainic Acid results in decreased activity of ACO2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Kainic Acid results in decreased activity of ACO2 protein] |
CTD |
PMID:11520895 |
|
NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261
|
|
G |
Acp1 |
acid phosphatase 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of ACP1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 6:47,506,380...47,522,021
Ensembl chr 6:47,506,380...47,522,021
|
|
G |
Adk |
adenosine kinase |
increases expression |
ISO |
Kainic Acid results in increased expression of ADK mRNA |
CTD |
PMID:17997037 |
|
NCBI chr15:2,863,241...3,246,453
Ensembl chr15:2,863,244...3,246,510
|
|
G |
Adnp |
activity-dependent neuroprotector homeobox |
multiple interactions decreases expression |
EXP |
Enzyme Inhibitors inhibits the reaction [Kainic Acid results in decreased expression of ADNP protein] Kainic Acid results in decreased expression of ADNP mRNA; Kainic Acid results in decreased expression of ADNP protein |
CTD |
PMID:18375135 |
|
NCBI chr 3:156,886,921...156,921,500
Ensembl chr 3:156,891,381...156,917,312
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
increases response to substance |
ISO |
ADRA1B protein results in increased susceptibility to Kainic Acid |
CTD |
PMID:19125850 |
|
NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
increases expression multiple interactions |
EXP ISO |
Kainic Acid results in increased expression of AIF1 protein [cyanoginosin LR co-treated with Kainic Acid] results in increased expression of AIF1 protein NADP inhibits the reaction [Kainic Acid results in increased expression of AIF1 protein] |
CTD |
PMID:32057834 PMID:34352349 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases localization multiple interactions |
ISO |
Kainic Acid results in increased localization of AIFM1 protein Minocycline inhibits the reaction [Kainic Acid results in increased localization of AIFM1 protein] |
CTD |
PMID:16469440 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
increases expression |
EXP |
Kainic Acid results in increased expression of ALOX5AP mRNA |
CTD |
PMID:19700661 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
Kainic Acid results in increased expression of APAF1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
multiple interactions |
EXP |
[Raloxifene Hydrochloride co-treated with Kainic Acid] results in increased expression of APEX1 mRNA |
CTD |
PMID:16120186 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Apoe |
apolipoprotein E |
decreases expression |
ISO |
Kainic Acid results in decreased expression of APOE mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
increases expression |
EXP ISO |
Kainic Acid results in increased expression of ARC mRNA; Kainic Acid results in increased expression of ARC protein |
CTD |
PMID:17632064 PMID:30557575 |
|
NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378
|
|
G |
Atf7ip |
activating transcription factor 7 interacting protein |
decreases expression |
EXP |
Kainic Acid results in decreased expression of ATF7IP mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 4:169,385,872...169,471,652
Ensembl chr 4:169,385,872...169,471,650
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases expression |
EXP |
NADP inhibits the reaction [Kainic Acid results in increased expression of ATG5 protein] |
CTD |
PMID:32057834 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
B4galt2 |
beta-1,4-galactosyltransferase 2 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of B4GALT2 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 5:131,412,541...131,422,573
Ensembl chr 5:131,412,541...131,421,013
|
|
G |
Bag3 |
BAG cochaperone 3 |
increases expression |
EXP |
Kainic Acid results in increased expression of BAG3 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP ISO |
Kainic Acid results in increased expression of BAX mRNA; Kainic Acid results in increased expression of BAX protein oridonin inhibits the reaction [Kainic Acid results in increased expression of BAX mRNA] EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]] Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of BAX protein] |
CTD |
PMID:18711747 PMID:19700661 PMID:25453207 PMID:31430510 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO EXP |
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione inhibits the reaction [Kainic Acid results in decreased expression of BCL2 protein]; 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione promotes the reaction [Valproic Acid inhibits the reaction [Kainic Acid results in decreased expression of BCL2 protein]]; Valproic Acid inhibits the reaction [Kainic Acid results in decreased expression of BCL2 protein] Kainic Acid results in decreased expression of BCL2 mRNA oridonin inhibits the reaction [Kainic Acid results in decreased expression of BCL2 mRNA] |
CTD |
PMID:25453207 PMID:31430510 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
EXP |
[Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of BDNF mRNA]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of BDNF mRNA] Kainic Acid results in increased expression of BDNF mRNA; Kainic Acid results in increased expression of BDNF protein |
CTD |
PMID:1641125 PMID:9073163 PMID:11279263 PMID:16166269 PMID:17827730 PMID:19700661 More...
|
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
EXP |
NADP inhibits the reaction [Kainic Acid results in increased expression of BECN1 protein] |
CTD |
PMID:32057834 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
C1qb |
complement C1q B chain |
increases expression multiple interactions |
ISO EXP |
Kainic Acid results in increased expression of C1QB mRNA Phenobarbital inhibits the reaction [Kainic Acid results in increased expression of C1QB mRNA] Kainic Acid results in increased expression of C1QB mRNA; Kainic Acid results in increased expression of C1QB protein |
CTD |
PMID:7870303 PMID:17997037 |
|
NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407
|
|
G |
C4b |
complement C4B |
increases expression |
ISO |
Kainic Acid results in increased expression of C4B mRNA |
CTD |
PMID:17997037 |
|
NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681
|
|
G |
Calb1 |
calbindin 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of CALB1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions increases phosphorylation |
ISO |
cyanoginosin LR inhibits the reaction [Kainic Acid results in increased phosphorylation of CAMK2A protein] |
CTD |
PMID:34352349 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
decreases expression |
ISO |
Kainic Acid results in decreased expression of CAMK4 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Capns1 |
calpain, small subunit 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of CAPNS1 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 1:85,444,613...85,454,861
Ensembl chr 1:85,444,608...85,454,795
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases cleavage increases expression |
ISO EXP |
Kainic Acid results in increased activity of CASP3 protein oridonin inhibits the reaction [Kainic Acid results in increased activity of CASP3 protein] EPO protein inhibits the reaction [Kainic Acid results in increased expression of CASP3 protein] Kainic Acid results in increased cleavage of CASP3 protein Kainic Acid results in increased expression of CASP3 mRNA; Kainic Acid results in increased expression of CASP3 protein 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione inhibits the reaction [Kainic Acid results in increased cleavage of CASP3 protein]; 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione promotes the reaction [Valproic Acid inhibits the reaction [Kainic Acid results in increased cleavage of CASP3 protein]]; Minocycline inhibits the reaction [Kainic Acid results in increased activity of CASP3 protein]; Valproic Acid inhibits the reaction [Kainic Acid results in increased cleavage of CASP3 protein] |
CTD |
PMID:16469440 PMID:18711747 PMID:19700661 PMID:25453207 PMID:31430510 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
decreases expression decreases activity multiple interactions |
ISO EXP |
Kainic Acid results in decreased expression of CAT mRNA; Kainic Acid results in decreased expression of CAT protein Kainic Acid results in decreased activity of CAT protein oridonin inhibits the reaction [Kainic Acid results in decreased activity of CAT protein] |
CTD |
PMID:29208536 PMID:31430510 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cck |
cholecystokinin |
decreases expression |
EXP |
Kainic Acid results in decreased expression of CCK protein |
CTD |
PMID:7774662 |
|
NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of CCL2 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
EXP |
Kainic Acid results in increased expression of CCNE1 protein |
CTD |
PMID:12941380 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
EXP |
Kainic Acid results in increased expression of CD68 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cdc42 |
cell division cycle 42 |
increases expression |
EXP |
Kainic Acid results in increased expression of CDC42 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdh13 |
cadherin 13 |
increases expression |
ISO |
Kainic Acid results in increased expression of CDH13 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of CDK2 protein |
CTD |
PMID:12941380 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression |
ISO |
Kainic Acid results in increased expression of CEACAM1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Chgb |
chromogranin B |
increases expression |
EXP |
Kainic Acid results in increased expression of CHGB mRNA |
CTD |
PMID:9427505 |
|
NCBI chr 3:120,043,824...120,057,169
Ensembl chr 3:120,043,738...120,057,166
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of CITED2 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
|
|
G |
Clu |
clusterin |
increases expression multiple interactions |
EXP |
Kainic Acid results in increased expression of CLU mRNA; Kainic Acid results in increased expression of CLU protein Phenobarbital inhibits the reaction [Kainic Acid results in increased expression of CLU mRNA] |
CTD |
PMID:7870303 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of CNR1 mRNA |
CTD |
PMID:22079489 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnrip1 |
cannabinoid receptor interacting protein 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of CNRIP1 mRNA |
CTD |
PMID:22079489 |
|
NCBI chr14:91,462,877...91,492,739
Ensembl chr14:91,462,647...91,492,735
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Kainic Acid results in increased expression of COL1A1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of CRHR1 mRNA |
CTD |
PMID:12093084 |
|
NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481
|
|
G |
Ctsb |
cathepsin B |
multiple interactions increases expression |
EXP |
NADP inhibits the reaction [Kainic Acid results in increased expression of CTSB protein] |
CTD |
PMID:32057834 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
multiple interactions increases expression |
EXP |
NADP inhibits the reaction [Kainic Acid results in increased expression of CTSD protein] |
CTD |
PMID:32057834 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctss |
cathepsin S |
increases expression |
ISO |
Kainic Acid results in increased expression of CTSS mRNA; Kainic Acid results in increased expression of CTSS protein |
CTD |
PMID:17997037 |
|
NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G |
Ctsz |
cathepsin Z |
increases expression |
ISO |
Kainic Acid results in increased expression of CTSZ mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 3:163,224,875...163,235,645
Ensembl chr 3:163,224,875...163,235,645
|
|
G |
Cycs |
cytochrome c, somatic |
increases localization multiple interactions increases expression |
ISO EXP |
Kainic Acid results in increased localization of CYCS protein Minocycline inhibits the reaction [Kainic Acid results in increased localization of CYCS protein] Kainic Acid results in increased expression of CYCS mRNA |
CTD |
PMID:16469440 PMID:19700661 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Dgcr6 |
DiGeorge syndrome critical region gene 6 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of DGCR6 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr11:82,927,725...82,932,823
Ensembl chr11:82,927,725...82,932,823
|
|
G |
Dhx36 |
DEAH-box helicase 36 |
increases expression |
ISO |
Kainic Acid results in increased expression of DHX36 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 2:146,856,469...146,894,577
Ensembl chr 2:146,856,469...146,894,572
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
increases expression |
EXP |
Kainic Acid results in increased expression of DIABLO mRNA |
CTD |
PMID:19700661 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases response to substance |
ISO |
DRD2 protein results in decreased susceptibility to Kainic Acid |
CTD |
PMID:11860278 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Egr1 |
early growth response 1 |
decreases expression affects expression |
ISO EXP |
Kainic Acid results in decreased expression of EGR1 mRNA Kainic Acid affects the expression of EGR1 mRNA |
CTD |
PMID:17997037 PMID:19700661 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
[cyanoginosin LR co-treated with Kainic Acid] results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:34352349 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
EXP |
kainic acid increases phosphorylation of Eif2s1 in rat neurons |
RGD |
PMID:17251432 |
RGD:10755427 |
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4a3 |
eukaryotic translation initiation factor 4A3 |
increases expression |
EXP |
Kainic Acid results in increased expression of EIF4A3 protein |
CTD |
PMID:17632064 |
|
NCBI chr10:104,549,038...104,559,032
Ensembl chr10:104,549,038...104,559,057
|
|
G |
Emc3 |
ER membrane protein complex subunit 3 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of EMC3 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 4:146,663,065...146,678,976
Ensembl chr 4:146,663,067...146,679,029
|
|
G |
En2 |
engrailed homeobox 2 |
affects response to substance decreases expression |
ISO |
EN2 protein affects the susceptibility to Kainic Acid Kainic Acid results in decreased expression of EN2 mRNA |
CTD |
PMID:19186208 |
|
NCBI chr 4:7,221,096...7,226,943
Ensembl chr 4:7,221,096...7,226,943
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of ENC1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
EPO protein inhibits the reaction [Kainic Acid results in decreased expression of EPOR protein]; EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]; EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]; EPO protein inhibits the reaction [Kainic Acid results in increased expression of CASP3 protein]; EPO protein inhibits the reaction [Kainic Acid results in increased expression of GFAP protein]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of EPOR protein]]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]] |
CTD |
PMID:18711747 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Epor |
erythropoietin receptor |
multiple interactions decreases expression |
ISO EXP |
EPO protein inhibits the reaction [Kainic Acid results in decreased expression of EPOR protein]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of EPOR protein]]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in increased expression of BAX protein]] |
CTD |
PMID:18711747 |
|
NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257
|
|
G |
Etfb |
electron transfer flavoprotein subunit beta |
decreases expression |
ISO |
Kainic Acid results in decreased expression of ETFB mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:93,851,908...93,866,072
Ensembl chr 1:93,851,858...93,866,068
|
|
G |
Fbxw5 |
F-box and WD repeat domain containing 5 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of FBXW5 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 3:8,322,543...8,327,092
Ensembl chr 3:8,322,543...8,327,092
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of FGF2 mRNA |
CTD |
PMID:7649223 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
increases expression |
EXP |
Kainic Acid results in increased expression of FGF5 mRNA |
CTD |
PMID:7649223 |
|
NCBI chr14:11,323,827...11,346,164
Ensembl chr14:11,325,334...11,345,997
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of FGFR1 mRNA |
CTD |
PMID:7649223 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression decreases expression |
ISO EXP |
10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone inhibits the reaction [Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; [Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of FOS protein; Dizocilpine Maleate inhibits the reaction [[Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of FOS protein]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of FOS protein] Kainic Acid results in increased expression of FOS mRNA; Kainic Acid results in increased expression of FOS protein [Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; [Phenytoin co-treated with Drugs, Chinese Herbal] inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]; Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]; Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; Diazepam inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]; dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of FOS protein]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of FOS protein] Kainic Acid results in decreased expression of FOS mRNA |
CTD |
PMID:7655348 PMID:7887109 PMID:8417141 PMID:8758711 PMID:15723099 PMID:16686654 PMID:17827730 PMID:17997037 PMID:26348896 More...
|
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
increases expression |
EXP |
Kainic Acid results in increased expression of FOSL2 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Fxyd1 |
FXYD domain-containing ion transport regulator 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of FXYD1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:86,287,163...86,291,478
Ensembl chr 1:86,287,165...86,291,278
|
|
G |
Gabrb1 |
gamma-aminobutyric acid type A receptor subunit beta1 |
increases expression multiple interactions |
ISO |
Kainic Acid results in increased expression of GABRB1 mRNA Quercetin inhibits the reaction [Kainic Acid results in increased expression of GABRB1 mRNA] |
CTD |
PMID:27386150 |
|
NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948
|
|
G |
Gabrb3 |
gamma-aminobutyric acid type A receptor subunit beta 3 |
multiple interactions increases expression |
ISO |
Quercetin inhibits the reaction [Kainic Acid results in increased expression of GABRB3 mRNA] |
CTD |
PMID:27386150 |
|
NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of GAD1 mRNA |
CTD |
PMID:16797850 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of GAD2 mRNA |
CTD |
PMID:16797850 |
|
NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
EXP |
Kainic Acid results in increased expression of GADD45A mRNA; Kainic Acid results in increased expression of GADD45A protein |
CTD |
PMID:20955365 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
decreases expression |
ISO |
Kainic Acid results in decreased expression of GADD45B mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
decreases expression |
ISO |
Kainic Acid results in decreased expression of GADD45G mRNA |
CTD |
PMID:17997037 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Gap43 |
growth associated protein 43 |
multiple interactions increases expression |
EXP |
Dizocilpine Maleate inhibits the reaction [Kainic Acid results in increased expression of GAP43 mRNA]; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of GAP43 mRNA] |
CTD |
PMID:8774942 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 |
increases expression |
ISO |
Kainic Acid results in increased expression of GCNT2 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression multiple interactions |
EXP ISO |
Kainic Acid results in increased expression of GFAP mRNA; Kainic Acid results in increased expression of GFAP protein NADP inhibits the reaction [Kainic Acid results in increased expression of GFAP protein] EPO protein inhibits the reaction [Kainic Acid results in increased expression of GFAP protein] PTGS2 affects the reaction [Kainic Acid results in increased expression of GFAP mRNA] |
CTD |
PMID:17997037 PMID:18711747 PMID:19700661 PMID:21589914 PMID:22790971 PMID:32057834 More...
|
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Glul |
glutamate-ammonia ligase |
multiple interactions decreases expression |
EXP |
oridonin inhibits the reaction [Kainic Acid results in decreased expression of GLUL mRNA] |
CTD |
PMID:31430510 |
|
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of GPX1 protein |
CTD |
PMID:29208536 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
multiple interactions increases phosphorylation decreases expression |
EXP ISO |
2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Kainic Acid results in decreased expression of GRIA1 protein]; Kainic Acid binds to and results in increased activity of GRIA1 protein; Urethane inhibits the reaction [Kainic Acid binds to and results in increased activity of GRIA1 protein] Kainic Acid results in increased phosphorylation of GRIA1 protein Kainic Acid results in decreased expression of GRIA1 mRNA Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA1 mRNA]; Kainic Acid inhibits the reaction [cyanoginosin LR results in increased expression of and results in increased phosphorylation of GRIA1 protein]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIA1 mRNA] Kainic Acid results in decreased expression of GRIA1 mRNA; Kainic Acid results in decreased expression of GRIA1 protein |
CTD |
PMID:7529610 PMID:11812690 PMID:17585341 PMID:21589914 PMID:34352349 |
|
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
multiple interactions increases methylation decreases expression affects response to substance |
EXP ISO |
Kainic Acid binds to and results in increased activity of GRIA2 protein; Urethane inhibits the reaction [Kainic Acid binds to and results in increased activity of GRIA2 protein] Kainic Acid results in increased methylation of GRIA2 gene Kainic Acid results in decreased expression of GRIA2 mRNA Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA2 mRNA]; RG108 inhibits the reaction [Kainic Acid results in increased methylation of GRIA2 gene] GRIA2 protein affects the susceptibility to Kainic Acid |
CTD |
PMID:7529610 PMID:10551584 PMID:11812690 PMID:21589914 PMID:24098468 |
|
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
decreases expression multiple interactions increases expression |
EXP ISO |
Kainic Acid results in decreased expression of GRIA3 mRNA celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA3 mRNA] Kainic Acid results in increased expression of GRIA3 mRNA |
CTD |
PMID:7529610 PMID:21589914 |
|
NCBI chr X:120,238,515...120,504,106
Ensembl chr X:120,238,534...120,504,096
|
|
G |
Gria4 |
glutamate ionotropic receptor AMPA type subunit 4 |
decreases expression multiple interactions |
ISO |
Kainic Acid results in decreased expression of GRIA4 mRNA celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIA4 mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 8:1,562,118...2,035,035
Ensembl chr 8:1,562,119...2,034,979
|
|
G |
Grik1 |
glutamate ionotropic receptor kainate type subunit 1 |
decreases expression increases expression multiple interactions |
ISO |
Kainic Acid results in decreased expression of GRIK1 mRNA Kainic Acid results in increased expression of GRIK1 mRNA Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIK1 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIK1 mRNA] |
CTD |
PMID:21589914 PMID:29208536 |
|
NCBI chr11:27,169,739...27,571,131
Ensembl chr11:27,169,740...27,570,645
|
|
G |
Grik2 |
glutamate ionotropic receptor kainate type subunit 2 |
increases expression multiple interactions |
ISO |
Kainic Acid results in increased expression of GRIK2 mRNA [Celecoxib co-treated with Kainic Acid] results in decreased expression of GRIK2 mRNA |
CTD |
PMID:17997037 PMID:21589914 PMID:29208536 |
|
NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375
|
|
G |
Grik3 |
glutamate ionotropic receptor kainate type subunit 3 |
decreases expression multiple interactions |
ISO |
Kainic Acid results in decreased expression of GRIK3 mRNA [Celecoxib co-treated with Kainic Acid] results in decreased expression of GRIK3 mRNA |
CTD |
PMID:21589914 |
|
NCBI chr 5:137,767,865...137,989,617
Ensembl chr 5:137,767,865...137,984,307
|
|
G |
Grik4 |
glutamate ionotropic receptor kainate type subunit 4 |
multiple interactions decreases expression |
ISO |
[Celecoxib co-treated with Kainic Acid] results in decreased expression of GRIK4 mRNA; Kainic Acid promotes the reaction [cyanoginosin LR affects the localization of GRIK4 protein] Kainic Acid results in decreased expression of GRIK4 mRNA |
CTD |
PMID:21589914 PMID:34352349 |
|
NCBI chr 8:42,903,043...43,331,990
Ensembl chr 8:42,905,056...43,193,751
|
|
G |
Grik5 |
glutamate ionotropic receptor kainate type subunit 5 |
multiple interactions decreases expression |
ISO |
Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIK5 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIK5 mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 1:80,605,878...80,667,896
Ensembl chr 1:80,605,892...80,667,125
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
multiple interactions affects expression decreases expression |
ISO EXP |
celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN1 mRNA] Kainic Acid affects the expression of GRIN1 |
CTD |
PMID:21589914 PMID:23159308 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
decreases expression multiple interactions |
ISO |
Kainic Acid results in decreased expression of GRIN2A mRNA celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2A mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions decreases expression |
ISO |
celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2B mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Grin2c |
glutamate ionotropic receptor NMDA type subunit 2C |
decreases expression multiple interactions |
ISO |
Kainic Acid results in decreased expression of GRIN2C mRNA Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2C mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN2C mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr10:100,488,430...100,507,083
Ensembl chr10:100,488,431...100,506,427
|
|
G |
Grin2d |
glutamate ionotropic receptor NMDA type subunit 2D |
decreases expression multiple interactions |
ISO |
Kainic Acid results in decreased expression of GRIN2D mRNA Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2D mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN2D mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 1:96,306,871...96,346,994
Ensembl chr 1:96,308,365...96,344,793
|
|
G |
Grin3a |
glutamate ionotropic receptor NMDA type subunit 3A |
multiple interactions decreases expression |
ISO |
Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN3A mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN3A mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 5:64,006,847...64,206,408
Ensembl chr 5:64,009,980...64,206,085
|
|
G |
Grin3b |
glutamate ionotropic receptor NMDA type subunit 3B |
decreases expression multiple interactions |
ISO |
Kainic Acid results in decreased expression of GRIN3B mRNA celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN3B mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 7:9,730,861...9,737,183
Ensembl chr 7:9,730,862...9,737,183
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases activity decreases phosphorylation multiple interactions |
ISO |
Kainic Acid results in decreased activity of GSK3B protein Kainic Acid results in decreased phosphorylation of GSK3B protein 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione inhibits the reaction [Kainic Acid results in decreased phosphorylation of GSK3B protein]; 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione promotes the reaction [Valproic Acid inhibits the reaction [Kainic Acid results in decreased phosphorylation of GSK3B protein]]; Valproic Acid inhibits the reaction [Kainic Acid results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:18619545 PMID:25453207 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions decreases activity |
EXP |
oridonin inhibits the reaction [Kainic Acid results in decreased activity of GSR protein] |
CTD |
PMID:31430510 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hcn1 |
hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 |
multiple interactions decreases expression |
EXP |
Kainic Acid promotes the reaction [REST protein binds to HCN1 intron]; REST mutant form inhibits the reaction [Kainic Acid promotes the reaction [REST protein binds to HCN1 intron]]; REST mutant form inhibits the reaction [Kainic Acid results in decreased expression of HCN1 mRNA]; REST mutant form inhibits the reaction [Kainic Acid results in decreased expression of HCN1 protein] Kainic Acid results in decreased expression of HCN1 mRNA; Kainic Acid results in decreased expression of HCN1 protein |
CTD |
PMID:21905079 |
|
NCBI chr 2:49,495,771...49,899,983
Ensembl chr 2:49,495,771...49,899,774
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions increases expression |
EXP |
Kainic Acid results in increased expression of and affects the localization of HMGB1 protein; perampanel inhibits the reaction [Kainic Acid results in increased expression of and affects the localization of HMGB1 protein] Kainic Acid results in increased expression of HMGB1 mRNA |
CTD |
PMID:36669621 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of HMOX1 mRNA |
CTD |
PMID:7655348 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Homer1 |
homer scaffold protein 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of HOMER1 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785
|
|
G |
Hpca |
hippocalcin |
decreases response to substance |
ISO |
HPCA protein results in decreased susceptibility to Kainic Acid |
CTD |
PMID:15607944 |
|
NCBI chr 5:141,455,616...141,466,252
Ensembl chr 5:141,455,613...141,463,841
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of HSD11B1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
ISO |
[Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of HSPA1A protein; Dizocilpine Maleate inhibits the reaction [[Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of HSPA1A protein]; GYKI 52466 inhibits the reaction [[Kainic Acid co-treated with dihydroxyethyldithiocarbamate] results in increased expression of HSPA1A protein] |
CTD |
PMID:16686654 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of IDI1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
EXP |
Kainic Acid results in decreased expression of IL10 protein |
CTD |
PMID:15591643 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12a |
interleukin 12A |
affects response to substance |
ISO |
IL12A protein affects the susceptibility to Kainic Acid |
CTD |
PMID:15474355 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il1b |
interleukin 1 beta |
increases secretion increases expression multiple interactions |
EXP ISO |
Kainic Acid results in increased secretion of IL1B protein Kainic Acid results in increased expression of IL1B mRNA; Kainic Acid results in increased expression of IL1B protein PTGS2 affects the reaction [Kainic Acid results in increased expression of IL1B mRNA] Minocycline inhibits the reaction [Kainic Acid results in increased secretion of IL1B protein]; oridonin inhibits the reaction [Kainic Acid results in increased expression of IL1B protein]; perampanel inhibits the reaction [Kainic Acid results in increased expression of IL1B protein] |
CTD |
PMID:7655348 PMID:11306611 PMID:21589914 PMID:31430510 PMID:36669621 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases response to substance multiple interactions increases expression |
ISO EXP |
IL6 protein results in increased susceptibility to Kainic Acid oridonin inhibits the reaction [Kainic Acid results in increased expression of IL6 protein] Kainic Acid results in increased expression of IL6 mRNA PTGS2 affects the reaction [Kainic Acid results in increased expression of IL6 mRNA] |
CTD |
PMID:12836160 PMID:21589914 PMID:31430510 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgam |
integrin subunit alpha M |
increases expression multiple interactions |
ISO |
Kainic Acid results in increased expression of ITGAM mRNA PTGS2 affects the reaction [Kainic Acid results in increased expression of ITGAM mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Jagn1 |
jagunal homolog 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of JAGN1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 4:146,591,577...146,596,287
Ensembl chr 4:146,591,510...146,596,288
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions decreases expression |
ISO EXP |
EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]; EPOR protein promotes the reaction [EPO protein inhibits the reaction [Kainic Acid results in decreased expression of JAK2 protein]] |
CTD |
PMID:18711747 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
[Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]; Diazepam inhibits the reaction [Kainic Acid results in increased expression of JUN protein]; dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]; dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of JUN protein]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of JUN protein] Kainic Acid results in increased expression of JUN mRNA; Kainic Acid results in increased expression of JUN protein |
CTD |
PMID:8417141 PMID:15723099 PMID:17827730 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
decreases expression increases expression |
ISO EXP |
Kainic Acid results in decreased expression of JUNB mRNA Kainic Acid results in increased expression of JUNB mRNA |
CTD |
PMID:17997037 PMID:19700661 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kalrn |
kalirin, RhoGEF kinase |
increases expression |
EXP |
Kainic Acid results in increased expression of KALRN mRNA |
CTD |
PMID:19700661 |
|
NCBI chr11:66,198,155...66,803,166
Ensembl chr11:66,198,173...66,797,610
|
|
G |
Kcnc2 |
potassium voltage-gated channel subfamily C member 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of KCNC2 protein |
CTD |
PMID:7643197 |
|
NCBI chr 7:47,700,035...47,883,979
Ensembl chr 7:47,700,288...47,883,968
|
|
G |
Kcnc4 |
potassium voltage-gated channel subfamily C member 4 |
decreases expression |
EXP |
Kainic Acid results in decreased expression of KCNC4 protein |
CTD |
PMID:21905079 |
|
NCBI chr 2:195,063,967...195,100,244
Ensembl chr 2:195,071,769...195,099,233
|
|
G |
Kcnq2 |
potassium voltage-gated channel subfamily Q member 2 |
increases response to substance |
ISO |
KCNQ2 protein mutant form results in increased susceptibility to Kainic Acid |
CTD |
PMID:26910900 |
|
NCBI chr 3:168,194,776...168,253,831
Ensembl chr 3:168,195,357...168,275,071
|
|
G |
Kif20a |
kinesin family member 20A |
decreases expression |
ISO |
Kainic Acid results in decreased expression of KIF20A mRNA |
CTD |
PMID:17997037 |
|
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
|
|
G |
Klf10 |
KLF transcription factor 10 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of KLF10 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
EXP |
Kainic Acid promotes the reaction [Nicotine results in decreased activity of KNG1 protein alternative form] |
CTD |
PMID:7807204 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
increases expression |
EXP |
Kainic Acid results in increased expression of KRAS mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Lep |
leptin |
decreases response to substance |
ISO |
LEP protein results in decreased susceptibility to Kainic Acid |
CTD |
PMID:17993459 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lmo1 |
LIM domain only 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of LMO1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:163,132,338...163,168,521
Ensembl chr 1:163,132,339...163,168,522
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases expression |
EXP |
NADP inhibits the reaction [Kainic Acid results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:32057834 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions increases expression |
ISO |
PTGS2 affects the reaction [Kainic Acid results in increased expression of MAP2 mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Kainic Acid results in increased phosphorylation of MAPK1 protein cyanoginosin LR promotes the reaction [Kainic Acid results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:34352349 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases expression increases phosphorylation multiple interactions |
ISO |
Kainic Acid results in increased expression of MAPK3 mRNA Kainic Acid results in increased phosphorylation of MAPK3 protein cyanoginosin LR promotes the reaction [Kainic Acid results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17997037 PMID:34352349 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mast3 |
microtubule associated serine/threonine kinase 3 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of MAST3 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr16:18,636,764...18,663,852
Ensembl chr16:18,636,787...18,663,852
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases activity multiple interactions |
ISO |
Kainic Acid results in increased activity of MMP9 protein MMP9 protein affects the reaction [Kainic Acid results in decreased expression of NCAM1 protein modified form] |
CTD |
PMID:30772382 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpdz |
multiple PDZ domain crumbs cell polarity complex component |
affects response to substance |
ISO |
MPDZ protein affects the susceptibility to Kainic Acid |
CTD |
PMID:14960011 |
|
NCBI chr 5:95,766,112...95,920,531
Ensembl chr 5:95,766,118...95,920,499
|
|
G |
Mpeg1 |
macrophage expressed 1 |
increases expression |
ISO |
Kainic Acid results in increased expression of MPEG1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:209,452,176...209,456,692
Ensembl chr 1:209,452,133...209,458,855
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of MSMO1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|
G |
Mt1 |
metallothionein 1 |
increases expression decreases response to substance |
EXP ISO |
Kainic Acid results in increased expression of MT1A mRNA MT1 protein results in decreased susceptibility to Kainic Acid |
CTD |
PMID:7655348 PMID:10947810 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Mt2A |
metallothionein 2A |
decreases response to substance |
ISO |
MT2 protein results in decreased susceptibility to Kainic Acid |
CTD |
PMID:10947810 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Myo5b |
myosin Vb |
decreases expression |
ISO |
Kainic Acid results in decreased expression of MYO5B mRNA |
CTD |
PMID:17997037 |
|
NCBI chr18:68,038,759...68,341,568
Ensembl chr18:68,038,759...68,338,745
|
|
G |
Myo9a |
myosin IXA |
increases expression |
ISO |
Kainic Acid results in increased expression of MYO9A mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 8:60,149,234...60,352,330
Ensembl chr 8:60,149,234...60,350,514
|
|
G |
Naip6 |
NLR family, apoptosis inhibitory protein 6 |
increases expression |
EXP ISO |
Kainic Acid results in increased expression of NAIP mRNA; Kainic Acid results in increased expression of NAIP protein |
CTD |
PMID:12547647 PMID:15046874 |
|
NCBI chr 2:31,507,423...31,559,098
Ensembl chr 2:31,507,424...31,570,542
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
decreases expression multiple interactions |
EXP ISO |
Kainic Acid results in decreased expression of NCAM1 mRNA MMP9 protein affects the reaction [Kainic Acid results in decreased expression of NCAM1 protein modified form] |
CTD |
PMID:19700661 PMID:30772382 |
|
NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014
|
|
G |
Nefl |
neurofilament light chain |
increases secretion |
EXP |
Kainic Acid results in increased secretion of NEFL protein |
CTD |
PMID:34677616 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization |
ISO |
Kainic Acid affects the localization of NFE2L2 protein |
CTD |
PMID:18619545 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions increases expression decreases expression |
EXP |
2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Kainic Acid results in decreased expression of NOS1 protein] Kainic Acid results in increased expression of NOS1 mRNA; Kainic Acid results in increased expression of NOS1 protein |
CTD |
PMID:17585341 PMID:18375135 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
ISO EXP |
Kainic Acid results in increased expression of NOS2 mRNA Kainic Acid results in increased expression of NOS2 mRNA; Kainic Acid results in increased expression of NOS2 protein PTGS2 affects the reaction [Kainic Acid results in increased expression of NOS2 mRNA] [Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of NOS2 mRNA]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of NOS2 mRNA]; Curcumin inhibits the reaction [Kainic Acid results in increased expression of NOS2 mRNA] |
CTD |
PMID:17827730 PMID:18375135 PMID:21589914 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npy |
neuropeptide Y |
decreases response to substance multiple interactions increases expression |
ISO EXP |
NPY protein results in decreased susceptibility to Kainic Acid Thiopental inhibits the reaction [Kainic Acid results in increased expression of NPY mRNA] |
CTD |
PMID:9427505 PMID:15451008 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
decreases expression increases expression |
ISO EXP |
Kainic Acid results in decreased expression of NR4A1 mRNA Kainic Acid results in increased expression of NR4A1 mRNA |
CTD |
PMID:17997037 PMID:19700661 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
increases expression |
EXP ISO |
Kainic Acid results in increased expression of NR4A2 mRNA Kainic Acid results in increased expression of NR4A2 protein |
CTD |
PMID:19700661 PMID:24813937 |
|
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
increases expression |
EXP |
Kainic Acid results in increased expression of NR4A3 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
|
|
G |
Nrp2 |
neuropilin 2 |
affects response to substance |
ISO |
NRP2 protein affects the susceptibility to Kainic Acid |
CTD |
PMID:18657176 |
|
NCBI chr 9:64,122,815...64,238,007
Ensembl chr 9:64,123,132...64,237,958
|
|
G |
Ntn1 |
netrin 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of NTN1 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr10:52,899,933...53,098,591
Ensembl chr10:52,899,934...53,085,326
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of NTRK2 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Nudcd2 |
NudC domain containing 2 |
increases expression |
ISO |
Kainic Acid results in increased expression of NUDCD2 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr10:25,163,247...25,168,738
Ensembl chr10:25,163,220...25,168,738
|
|
G |
Nudt4 |
nudix hydrolase 4 |
increases expression |
ISO |
Kainic Acid results in increased expression of NUDT4 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 7:30,188,100...30,204,615
Ensembl chr 7:30,188,100...30,204,615
|
|
G |
Otx2 |
orthodenticle homeobox 2 |
decreases expression |
EXP |
Kainic Acid results in decreased expression of OTX2 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr15:21,942,233...21,953,034
Ensembl chr15:21,943,191...21,953,416
|
|
G |
Pak3 |
p21 (RAC1) activated kinase 3 |
decreases expression |
EXP |
Kainic Acid results in decreased expression of PAK3 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr X:107,116,308...107,374,342
Ensembl chr X:107,260,898...107,368,314
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases activity |
EXP |
Kainic Acid results in increased activity of PARP1 protein |
CTD |
PMID:28704930 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdyn |
prodynorphin |
multiple interactions affects expression increases expression |
EXP |
Diazepam inhibits the reaction [Kainic Acid results in increased expression of PDYN mRNA]; Kainic Acid results in decreased cleavage of and results in decreased secretion of PDYN protein; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of PDYN mRNA]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of PDYN mRNA] Kainic Acid affects the expression of PDYN mRNA |
CTD |
PMID:1465197 PMID:8417141 |
|
NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334
|
|
G |
Penk |
proenkephalin |
multiple interactions increases expression |
EXP |
Diazepam inhibits the reaction [Kainic Acid results in increased expression of PENK mRNA]; Pentobarbital inhibits the reaction [Kainic Acid results in increased expression of PENK mRNA]; Thiopental inhibits the reaction [Kainic Acid results in increased expression of PENK mRNA]; Valproic Acid inhibits the reaction [Kainic Acid results in increased expression of PENK mRNA] |
CTD |
PMID:8417141 PMID:9427505 |
|
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
|
|
G |
Pick1 |
protein interacting with PRKCA 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of PICK1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 7:110,796,623...110,816,850
Ensembl chr 7:110,797,117...110,816,848
|
|
G |
Pkp2 |
plakophilin 2 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of PKP2 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr11:84,661,783...84,727,730
Ensembl chr11:84,661,783...84,727,730
|
|
G |
Plod3 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of PLOD3 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr12:19,676,384...19,686,945
Ensembl chr12:19,676,386...19,686,960
|
|
G |
Ppif |
peptidylprolyl isomerase F |
increases response to substance |
ISO |
PPIF results in increased susceptibility to Kainic Acid |
CTD |
PMID:21378209 |
|
NCBI chr16:1,257,197...1,263,919
Ensembl chr16:1,257,106...1,263,913
|
|
G |
Ppp1r9b |
protein phosphatase 1, regulatory subunit 9B |
increases expression |
EXP |
Kainic Acid results in increased expression of PPP1R9B protein |
CTD |
PMID:17443789 |
|
NCBI chr10:79,938,055...79,954,085
Ensembl chr10:79,938,066...79,954,083
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
[cyanoginosin LR co-treated with Kainic Acid] results in increased phosphorylation of PRKCD protein |
CTD |
PMID:34352349 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases response to substance increases expression |
EXP ISO |
[Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of PTGS2 mRNA]; [diacetylcurcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of PTGS2 mRNA]; oridonin inhibits the reaction [Kainic Acid results in increased expression of PTGS2 protein] [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Dinoprost; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Dinoprostone; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Prostaglandin D2; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Thromboxane B2; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIA1 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIK1 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIK5 mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN2C mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN2D mRNA]; PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN3A mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of GFAP mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of IL1B mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of IL6 mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of ITGAM mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of MAP2 mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of NOS2 mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of RELA mRNA]; PTGS2 affects the reaction [Kainic Acid results in increased expression of TNF mRNA] Kainic Acid results in increased expression of PTGS2; Kainic Acid results in increased expression of PTGS2 mRNA; Kainic Acid results in increased expression of PTGS2 protein |
CTD |
PMID:11168565 PMID:12618123 PMID:17827730 PMID:18834901 PMID:19700661 PMID:21589914 PMID:31430510 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Qki |
QKI, KH domain containing RNA binding |
increases expression |
ISO |
Kainic Acid results in increased expression of QKI mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:50,387,716...50,501,568
Ensembl chr 1:50,387,698...50,498,831
|
|
G |
Rac1 |
Rac family small GTPase 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of RAC1 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rad23a |
RAD23 homolog A, nucleotide excision repair protein |
increases expression |
EXP |
Kainic Acid results in increased expression of RAD23A mRNA |
CTD |
PMID:19700661 |
|
NCBI chr19:23,313,563...23,320,702
Ensembl chr19:23,314,797...23,320,695
|
|
G |
Rasd1 |
ras related dexamethasone induced 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of RASD1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186
|
|
G |
Rbfox1 |
RNA binding fox-1 homolog 1 |
increases response to substance |
ISO |
RBFOX1 gene mutant form results in increased susceptibility to Kainic Acid |
CTD |
PMID:21623373 |
|
NCBI chr10:8,152,198...10,248,120
Ensembl chr10:8,152,198...9,686,659
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases expression |
ISO |
PTGS2 affects the reaction [Kainic Acid results in increased expression of RELA mRNA] |
CTD |
PMID:21589914 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rest |
RE1-silencing transcription factor |
increases expression multiple interactions |
EXP |
Kainic Acid results in increased expression of REST protein Kainic Acid promotes the reaction [REST protein binds to HCN1 intron]; REST mutant form inhibits the reaction [Kainic Acid promotes the reaction [REST protein binds to HCN1 intron]]; REST mutant form inhibits the reaction [Kainic Acid results in decreased expression of HCN1 mRNA]; REST mutant form inhibits the reaction [Kainic Acid results in decreased expression of HCN1 protein] |
CTD |
PMID:21905079 |
|
NCBI chr14:30,859,109...30,879,828
Ensembl chr14:30,862,553...30,894,354
|
|
G |
Rgs16 |
regulator of G-protein signaling 16 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of RGS16 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr13:65,887,668...65,892,862
Ensembl chr13:65,887,530...65,892,857
|
|
G |
Rhoa |
ras homolog family member A |
increases expression |
EXP |
Kainic Acid results in increased expression of RHOA mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of S1PR1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 2:203,624,752...203,629,110
Ensembl chr 2:203,621,587...203,629,681
|
|
G |
Sap30l |
SAP30-like |
decreases expression |
ISO |
Kainic Acid results in decreased expression of SAP30L mRNA |
CTD |
PMID:17997037 |
|
NCBI chr10:41,979,730...41,992,307
Ensembl chr10:41,979,687...41,987,658
|
|
G |
Sema4d |
semaphorin 4D |
increases expression |
EXP |
Kainic Acid results in increased expression of SEMA4D mRNA |
CTD |
PMID:19700661 |
|
NCBI chr17:13,430,324...13,537,146
Ensembl chr17:13,430,379...13,537,138
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions increases expression |
ISO |
Guanethidine inhibits the reaction [Kainic Acid results in increased expression of SERPINE1 mRNA]; Mecamylamine inhibits the reaction [Kainic Acid results in increased expression of SERPINE1 mRNA]; Phentolamine inhibits the reaction [Kainic Acid results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:15850565 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sfpq |
splicing factor proline and glutamine rich |
increases expression |
ISO |
Kainic Acid results in increased expression of SFPQ mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 5:139,338,034...139,353,476
Ensembl chr 5:139,338,075...139,353,472
|
|
G |
Sigmar1 |
sigma non-opioid intracellular receptor 1 |
multiple interactions |
EXP |
SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [Dextromethorphan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of FOS protein]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN mRNA]]; SIGMAR1 protein affects the reaction [dimemorfan inhibits the reaction [Kainic Acid results in increased expression of JUN protein]] |
CTD |
PMID:15723099 |
|
NCBI chr 5:56,904,155...56,907,012
Ensembl chr 5:56,904,159...56,907,017
|
|
G |
Sirt1 |
sirtuin 1 |
decreases expression increases expression |
ISO EXP |
Kainic Acid results in decreased expression of SIRT1 protein Kainic Acid results in increased expression of SIRT1 protein |
CTD |
PMID:18538940 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
increases expression |
EXP |
Kainic Acid results in increased expression of SLC11A2 |
CTD |
PMID:16552559 |
|
NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of SLC1A1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
multiple interactions increases expression |
ISO EXP |
[Kainic Acid co-treated with zinc chloride] results in decreased expression of SLC1A2 protein Ceftriaxone promotes the reaction [Kainic Acid results in increased expression of SLC1A2 protein] |
CTD |
PMID:19061913 PMID:28257918 |
|
NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Kainic Acid inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
increases response to substance |
ISO |
SLC6A2 protein results in increased susceptibility to Kainic Acid |
CTD |
PMID:15911120 |
|
NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357
|
|
G |
Slc8a3 |
solute carrier family 8 member A3 |
multiple interactions increases expression increases cleavage |
EXP |
2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Kainic Acid results in increased cleavage of SLC8A3 protein] Kainic Acid results in increased expression of SLC8A3 protein |
CTD |
PMID:17585341 PMID:20928830 |
|
NCBI chr 6:100,874,359...101,007,989
Ensembl chr 6:100,874,369...101,007,508
|
|
G |
Snrk |
SNF related kinase |
decreases expression |
ISO |
Kainic Acid results in decreased expression of SNRK mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 8:121,779,704...121,833,949
Ensembl chr 8:121,793,302...121,832,323
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of SOD1 protein |
CTD |
PMID:29208536 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression increases expression |
EXP ISO |
Kainic Acid results in decreased expression of SOD2 protein Kainic Acid results in decreased expression of SOD2 mRNA; Kainic Acid results in decreased expression of SOD2 protein Kainic Acid results in increased expression of SOD2 protein |
CTD |
PMID:10686417 PMID:29208536 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
increases expression |
EXP |
Kainic Acid results in increased expression of SPTAN1 protein modified form |
CTD |
PMID:22790971 |
|
NCBI chr 3:13,241,164...13,306,047
Ensembl chr 3:13,241,217...13,306,046
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression multiple interactions |
EXP |
Kainic Acid results in decreased expression of SQSTM1 protein NADP inhibits the reaction [Kainic Acid results in decreased expression of SQSTM1 protein] |
CTD |
PMID:32057834 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Sst |
somatostatin |
decreases expression |
ISO |
Kainic Acid results in decreased expression of SST mRNA |
CTD |
PMID:17997037 |
|
NCBI chr11:76,956,896...76,958,173
Ensembl chr11:76,956,896...76,958,173
|
|
G |
Tac1 |
tachykinin, precursor 1 |
decreases expression |
EXP |
Kainic Acid results in decreased expression of TAC1 protein |
CTD |
PMID:6205719 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tigar |
TP53 induced glycolysis regulatory phosphatase |
decreases expression multiple interactions |
EXP |
Kainic Acid results in decreased expression of TIGAR protein NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein] |
CTD |
PMID:32057834 |
|
NCBI chr 4:159,927,136...159,946,077
Ensembl chr 4:159,927,139...159,946,029 Ensembl chr 6:159,927,139...159,946,029
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions increases expression |
EXP |
perampanel inhibits the reaction [Kainic Acid results in increased expression of TLR4 protein] Kainic Acid results in increased expression of TLR4 mRNA; Kainic Acid results in increased expression of TLR4 protein |
CTD |
PMID:36669621 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO EXP |
PTGS2 affects the reaction [Kainic Acid results in increased expression of TNF mRNA]; TNF protein promotes the reaction [Kainic Acid results in increased uptake of Cobalt] oridonin inhibits the reaction [Kainic Acid results in increased expression of TNF protein] Kainic Acid results in increased expression of TNF mRNA; Kainic Acid results in increased expression of TNF protein |
CTD |
PMID:15869941 PMID:19700661 PMID:21589914 PMID:31430510 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
EXP |
Kainic Acid results in increased expression of TP53 protein |
CTD |
PMID:20955365 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trh |
thyrotropin releasing hormone |
decreases expression increases expression |
EXP |
Kainic Acid results in decreased expression of TRH mRNA Kainic Acid results in increased expression of TRH mRNA |
CTD |
PMID:10443546 |
|
NCBI chr 4:124,742,111...124,777,094
Ensembl chr 4:124,742,111...124,744,637
|
|
G |
Trhr |
thyrotropin releasing hormone receptor |
decreases expression |
EXP |
Kainic Acid results in decreased expression of TRHR protein |
CTD |
PMID:10443546 |
|
NCBI chr 7:75,348,672...75,393,310
Ensembl chr 7:75,348,672...75,393,309
|
|
G |
Tyrobp |
transmembrane immune signaling adaptor Tyrobp |
increases expression |
ISO |
Kainic Acid results in increased expression of TYROBP mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:85,672,931...85,676,856
Ensembl chr 1:85,672,994...85,676,848
|
|
G |
Uchl1 |
ubiquitin C-terminal hydrolase L1 |
increases expression |
EXP |
Kainic Acid results in increased expression of UCHL1 protein |
CTD |
PMID:22790971 |
|
NCBI chr14:41,485,031...41,495,590
Ensembl chr14:41,485,031...41,495,590
|
|
G |
Uhmk1 |
U2AF homology motif kinase 1 |
decreases expression |
ISO |
Kainic Acid results in decreased expression of UHMK1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr13:82,396,646...82,416,292
Ensembl chr13:82,401,187...82,416,292
|
|
G |
Uri1 |
URI1, prefoldin-like chaperone |
increases expression |
ISO |
Kainic Acid results in increased expression of URI1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 1:90,646,392...90,704,811
Ensembl chr 1:90,646,393...90,709,026
|
|
G |
Utp3 |
UTP3, small subunit processome component |
decreases expression |
ISO |
Kainic Acid results in decreased expression of UTP3 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr14:19,515,716...19,517,370
Ensembl chr14:19,515,669...19,517,396
|
|
G |
Vamp7 |
vesicle-associated membrane protein 7 |
decreases expression |
EXP |
Kainic Acid results in decreased expression of VAMP7 mRNA |
CTD |
PMID:19700661 |
|
NCBI chr12:16,728,486...16,764,261
Ensembl chr12:16,728,524...16,764,097
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Kainic Acid results in decreased expression of VEGFA mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wfs1 |
wolframin ER transmembrane glycoprotein |
increases expression |
ISO |
Kainic Acid results in increased expression of WFS1 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr14:73,810,478...73,834,993
Ensembl chr14:73,810,404...73,835,602
|
|
G |
Xpa |
XPA, DNA damage recognition and repair factor |
increases expression |
EXP |
Kainic Acid results in increased expression of XPA mRNA |
CTD |
PMID:19700661 |
|
NCBI chr 5:60,431,673...60,475,726
Ensembl chr 5:60,431,673...60,475,726
|
|
G |
Zcchc7 |
zinc finger CCHC-type containing 7 |
increases expression |
ISO |
Kainic Acid results in increased expression of ZCCHC7 mRNA |
CTD |
PMID:17997037 |
|
NCBI chr 5:58,992,558...59,173,308
Ensembl chr 5:58,993,290...59,173,300
|
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
affects expression |
ISO |
Lincomycin affects the expression of MR1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970
|
|
G |
RT1-A2 |
RT1 class Ia, locus A2 |
affects expression |
ISO |
Lincomycin affects the expression of HLA-E mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,870,939...4,910,183
|
|